Cristal Health: How AI can transform the diagnosis of neurodegenerative disease

CRIStal Health (CRIStal) is a spin out from the University of Oxford, established May 2019. CRIStal is a UK-based SME with modest revenues and is at an early growth-stage.

Our niche business area is applying innovative data science approaches to Mental Health and Dementia research and clinical service transformation. Unlike most spinouts we operate a mature business operation involving 11 NHS Trusts and their academic partners, providing secure access to over 2.7m electronic health records (EHR). CRIStal has a validated governance model for managing highly sensitive data. 

CRIStal provides data science consulting services and intends to become a global specialist in Precision Psychiatry using real-world, imaging and genomics data. 

CRIStal will focus on three key business areas (clinical trials including drug discovery, clinical service transformation and academic/industry research) of the global big data analytics in healthcare market, worth £13.8bn in 2017, projected to reach £55.4bn by 2025. 

Cristal Health’s aim is to accelerate the development of new treatments and service improvements in mental health by enhancing data extraction capabilities, data structuring and data linkage from EHRs. This will support trial recruitment and post surveillance studies; the two main aspects of the drug discovery pipeline.

We are a startup that is developing very quickly and we are looking for top data science talent to join us on this exciting venture.